INTRODUCTION
============

Hepatocellular adenoma (HCA) is a benign liver tumor composed of hepatocytes.[@B1] HCA represents a heterogeneous entity, and is subclassified into four groups according to genotype and phenotype: hepatocyte nuclear factor (HNF) 1α-inactivated HCA, β-catenin-activated HCA, inflammatory HCA, and unclassified HCA.[@B1] Theses subtypes vary greatly in their clinical and pathological features. Identifying the HCA subtype is important because it represents a way to understand the prognosis of HCA in terms of hepatocellular carcinoma (HCC) transformation. We present a case of β-catenin-activated HCA and discuss the histopathological findings with a review of the literature.

CASE SUMMARY
============

A 39-year-old man was admitted to our hospital to evaluate an asymptomatic hepatic mass detected incidentally during a health checkup. The patient did not have a history of alcoholism, androgenic steroid use, or metabolic syndrome. The subject\'s body mass index (BMI, kg/m^2^) was 20.7 (normal range, 18.50-24.99 kg/m^2^). Serum aspartate aminotransferase was 21 IU/L (normal range, 12-33 IU/L), alanine aminotransferase was 14 IU/L (normal range, 5-35 IU/L), and gamma-glutamyl transferase (GGT) was 31 IU/L (normal range, 12-73 IU/L). Other liver function tests were within normal limits. Hepatitis B virus surface antigen was negative, and the levels of tumor markers were all within normal ranges. Magnetic resonance imaging demonstrated a lobulated contoured hepatic mass located in segment VI that showed iso-intensity on T1-weighted images, heterogeneous high-intensity on T2-weighted images, and a focal signal drop, particularly at the periphery, on fat-suppressed T2-weighted images ([Fig. 1A](#F1){ref-type="fig"}), suggesting hepatocellular adenoma. A laparoscopic wedge resection was performed.

PATHOLOGICAL FINDINGS
=====================

A 5.2×3.6 cm sized, homogeneous, green colored hepatic mass was observed on the cut section ([Fig. 1B](#F1){ref-type="fig"}). The margins of the mass were relatively well-defined but not encapsulated. The mass was microscopically composed of benign hepatocytes arranged in one or two thick irregular cell plates with sharp demarcation from the surrounding non-tumoral liver ([Fig. 2A](#F2){ref-type="fig"}). The background liver was normal. Other characteristic pathological features of this mass included peliosis ([Fig. 2B](#F2){ref-type="fig"}), sinusoidal dilatation and inflammatory infiltrates ([Fig. 2C](#F2){ref-type="fig"}), diffuse steatosis ([Fig. 2D](#F2){ref-type="fig"}), cytoplasmic bile pigment and feathery degeneration of hepatocytes ([Fig. 2E](#F2){ref-type="fig"}), numerous unpaired arteries, and bile duct loss. An occasional pseudoglandular growth pattern and cytologic atypia were also observed ([Fig. 2F](#F2){ref-type="fig"}). Immunohistochemistry revealed that the tumor cells were positive for glutamine synthetase (GS) in a diffuse pattern ([Fig. 3A](#F3){ref-type="fig"}) and showed aberrant cytoplasmic and nuclear β-catenin expression ([Fig. 3B](#F3){ref-type="fig"}). The tumor cells were negative for two inflammation-related proteins, serum amyloid A and C reactive protein (SAA/CRP) and also negative for glypican 3. The final diagnosis was β-catenin-activated HCA based on the histological and immunohistochemical findings. No obvious recurrence of the tumor was detected post-operatively during the 7 month follow-up.

DISCUSSION
==========

HCA is a rare benign liver tumor (solitary or multiple) that most frequently develops in young women who are using oral contraceptives (OC). HCA is rare in children, men, and the elderly.[@B1] Most men developing HCA have been users of anabolic steroids for bodybuilding.[@B1],[@B2] Patients taking androgens for Fanconi anemia or acquired aplastic anemia are also at risk.[@B2] Obesity and alcohol intake have recently been shown to be risk factors for developing inflammatory HCA.[@B3] HCA can also occur in specific settings such as metabolic disease (glycogenosis, tyrosinemia, or galactosemia) but rarely in association with polycystic ovary syndrome or advanced-stage fatty liver disease.[@B4] Some small HCA may regress after withdrawal of OC or after menopause; however, they usually remain stable, or increase in size. Clinically significant hemorrhaging is observed in 20-25% of cases. Malignant transformation to HCC is rare but well-documented.[@B5]-[@B7]

HCA are classified into three main subgroups according to genotype: (1) inactivating mutations in the *HNF 1α* gene, (2) activating mutation in the *CTNNB1* gene that encodes β-catenin, and (3) activation of signal transducers and activators of transcription type 3 in the absence of ligand due to glycoprotein 130 mutants.[@B3]-[@B5],[@B7] A phenotypic classification is based on features of morphology and immunohistochemistry. Close relationships have been found between these molecular subgroups defined by genotype and their clinicopathological characteristics.[@B3]-[@B5],[@B7] This new genotype/phenotype subclassification of HCA was introduced by Bioulac-Sage and colleagues and is currently presented by the WHO Tumors of the Digestive System.[@B1],[@B5],[@B7] The *HNF 1α* biallelic somatic mutation is observed in 35-40% of HCA cases. It almost always occurs in women. HNF 1α-inactivated HCA is most highly steatotic, with a lack of expression of liver fatty acid binding protein (LFABP) in immunohistochemistry analyses. Significant inflammation and cellular atypia are absent. A *HNF 1α* germline mutation is observed in \<5% of HCA cases and can be associated with MODY 3 diabetes, particularly in children and young adults. The diagnosis of HNF 1α-inactivated HCA may be suggested by a radiologist due to the steatosis. The second type, an activating β-catenin mutation, is found in 10-15% HCA cases. This β-catenin activated HCA subtype is often associated with males as in our case or specific conditions (glycogenosis or administration of male hormone). Cytologic atypia and a pseudoglandular growth pattern are frequently observed. Immunohistochemistry studies show that this HCA subtype overexpresses β-catenin (nuclear and cytoplasmic) and GS. Because this group has a higher risk of malignant transformation into HCC than that of other subtypes, identifying β-catenin activated HCA subtype is extremely important. The third, inflammatory HCA, is observed in 45-60% of cases, and most patients with this subtype are women. Lesions are characterized by inflammatory infiltrates, thick-walled arteries, sinusoidal dilatation, and a ductular reaction. Inflammatory HCA is immunohistochemically characterized by increased expression of SAA/CRP at both the mRNA and protein levels. GS is usually absent, and LFABP is normally expressed in the non-tumoral liver parenchyma. GGT is frequently elevated in this group, with a biological inflammatory syndrome present. Additionally, more overweight patients (BMI \>25) are found in this group. A risk for malignant transformation is present, particularly for cases in which β-catenin is also mutated. Finally, \<10% of HCA is unclassified with non-mutated HNF 1α or β-catenin and without an inflammatory infiltrate.

van Aalten et al reported that the subtype classification was straightforward in \>90% of HCA cases using the immunohistochemical staining pattern and morphology.[@B8] Our case showed diffuse and strong positivity for GS and aberrant cytoplasmic and nuclear staining for β-catenin, so the diagnosis of β-catenin-activated HCA was made by immunohistochemistry ([Table 1](#T1){ref-type="table"}). However, the present case exhibited some unusual histological features such as diffuse steatosis, inflammatory infiltrates, and peliosis, which usually appear in inflammatory HCA. Therefore, our case should be distinguished from β-catenin-activated inflammatory HCA. Steatosis and inflammation are usually absent in β-catenin-activated HCA.[@B1],[@B5],[@B7],[@B9] However, Bordeaux\'s group has pointed out that β-catenin-activated HCA and inflammatory HCA have overlapping features of an inflammatory infiltrate, patchy steatosis, diffuse GS staining, and β-catenin mutation.[@B3] Inflammatory HCA is characterized by diffuse, strong expression of SAA or CRP in tumoral hepatocytes.[@B1],[@B3]-[@B5],[@B7] These markers are useful for distinguishing cases with overlapping histological features.[@B10] We excluded inflammatory HCA because no SAA/CRP expression was observed, which is necessary for a diagnosis of inflammatory HCA.

Despite that radiological imaging techniques have made great progress in identifying benign liver tumors, it is difficult to distinguish between different types of HCA (particularly β-catenin-activated HCA, which has variable and nonspecific radiologic findings).[@B11] Complete surgical removal and a careful pathological examination are necessary to prevent a potential misdiagnosis and identify β-catenin-activated HCA, which is prone to develop into HCC.
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![(A) Focal areas of signal loss at the periphery on fat-suppressed T2-weighted images. (B) Cut section of the gross specimen showed well-demarcated, greenish mass-like lesion without hemorrhage or cystic change.](cmh-19-185-g001){#F1}

![(A) The margin of the mass was non-encapsulated, and had a sharp demarcation (arrows) from the surrounding non-tumoral liver (hematoxylin and eosin \[H & E\] stain, ×40). The histological examination showed (B) peliosis (H & E stain, ×100), (C) sinusoidal dilatation and inflammatory infiltrates (H & E stain, ×200), and (D) steatotic hepatocytes (H & E stain, ×400). (E) Cytoplasmic bile pigment, feathery degeneration (H & E stain, ×400), (F) an occasional pseudoglandular growth pattern and cytologic atypia (H & E stain, ×400) were also observed.](cmh-19-185-g002){#F2}

![(A) Glutamine synthetase was strongly and diffusely expressed by tumoral hepatocytes (×200), and (B) Aberrant cytoplasmic and nuclear expression of β-catenin by tumoral hepatocytes (arrows) (×400).](cmh-19-185-g003){#F3}
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Clinicohistopathological features of hepatocellular adenoma (HCA)[@B1],[@B3]-[@B5],[@B7]
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^\*^10% of HCA also have mutant ß-catenin; ^†^Except if ß-catenin is mutated; ^‡^Aberrant cytoplasmic and nuclear expression.

Grading: +, mild; 2+, moderate; 3+, severe; -, absent.

HNF 1a, hepatocyte nuclear factor 1; SAA/CRP, serum amyloid A and C reactive protein; BMI, body mass index; ND, not done.
